Literature DB >> 24338338

Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis.

Ping Chen1, Jiang Zhu, Ding-Yi Liu, Hui-Yan Li, Nie Xu, Mei Hou.   

Abstract

The expression of survivin, an inhibitor of apoptosis can be seen in most tumors and is correlated with the angiogenic factor vascular endothelial growth factor (VEGF). But little is known about their contribution in small-cell lung cancer (SCLC). This study was designed to investigate the expression of survivin and VEGF in SCLC, and to explore their correlation with clinical-pathological feature and prognosis. Forty-five patients with pathological histology of SCLC were entered into this study. Forty-five cases of matched adjacent non-tumor samples and 10 samples of operated patients with benign lung tumor were also included as control. The expression of survivin and VEGF was detected by immunohistochemistry (IHC, SP). These two sets of data were processed and tested for correlation with major patients' characteristics, and overall survival. The correlations between survivin and VEGF expressions and the clinical-pathological features were evaluated by chi-square test. The correlation between survivin and VEGF expressions was analyzed by Spearman's rank correlation test; the overall survival was analyzed by the Kaplan-Meier method; and the relationship between clinical and pathological features and overall survival was analyzed by the Cox proportional hazard models. Positive expression rate of survivin and VEGF was significantly higher in SCLC than those of adjacent non-tumor tissues and benign lung tumor tissues (73.3 vs. 15.6 vs. 0 %, P < 0.05) and (75.6 vs. 20 vs. 0 %, P < 0.05), respectively. Survivin and VEGF expressions were significantly associated with lymph node metastasis (P = 0.003, 0.011) and clinical stage (P = 0.006, 0.021). The expression of survivin was significantly coincident with the expression of VEGF (r = 0.644, P = 0.000). The median overall survival in survivin positive group and VEGF positive group was significantly shorter than those in survivin negative and VEGF negative group, respectively (log-rank P = 0.000). Moreover, multivariate analysis showed that survivin expression (HR 0.224; 95 % CI 0.074-0.675; P = 0.008) and VEGF expression (HR 0.172; 95 % CI 0.054-0.559; P = 0.003) were statistically independent predictive factors of poorer prognosis for SCLC patients. Our results indicated that survivin and VEGF were over-expressed in small-cell lung cancer, each of them may be an independent poor prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24338338     DOI: 10.1007/s12032-013-0775-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3.

Authors:  Sachie Tanno; Yoshinobu Ohsaki; Kyoko Nakanishi; Eri Toyoshima; Kenjiro Kikuchi
Journal:  Lung Cancer       Date:  2004-10       Impact factor: 5.705

2.  High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer.

Authors:  Kyubo Kim; Eui Kyu Chie; Hong-Gyun Wu; Sang Gyun Kim; Seung-Hee Lee; Gyeong Hoon Kang; Chang Lim Hyun; Sung W Ha
Journal:  Int J Colorectal Dis       Date:  2011-03-19       Impact factor: 2.571

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

4.  A survivin gene signature predicts aggressive tumor behavior.

Authors:  Whitney Salz; Dan Eisenberg; Janet Plescia; David S Garlick; Robert M Weiss; Xue-Ru Wu; Tung-Tien Sun; Dario C Altieri
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Survivin monomer plays an essential role in apoptosis regulation.

Authors:  Marat S Pavlyukov; Nadezhda V Antipova; Maria V Balashova; Tatjana V Vinogradova; Evgenij P Kopantzev; Mihail I Shakhparonov
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

7.  Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC).

Authors:  Yu Yang; Jiang Zhu; Hongfeng Gou; Dan Cao; Ming Jiang; Mei Hou
Journal:  Med Oncol       Date:  2010-04-17       Impact factor: 3.064

8.  Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance.

Authors:  R Gonzalez; J M Silva; A Sanchez; G Dominguez; J M Garcia; X Q Chen; M Stroun; M Provencio; P España; P Anker; F Bonilla
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

9.  Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer.

Authors:  Toshihiko Iizasa; Hao Chang; Makoto Suzuki; Mizuto Otsuji; Sana Yokoi; Masako Chiyo; Shinichiro Motohashi; Kazuhiro Yasufuku; Yasuo Sekine; Akira Iyoda; Kiyoshi Shibuya; Kenzo Hiroshima; Takehiko Fujisawa
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

10.  Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome.

Authors:  Aziza Nassar; Diane Lawson; George Cotsonis; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-03
View more
  29 in total

1.  Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study.

Authors:  Jaya Nigam; Abhijit Chandra; Hasan Raza Kazmi; Anshuman Singh; Vishal Gupta; Devendra Parmar; Manoj Kumar Srivastava
Journal:  Med Oncol       Date:  2014-08-17       Impact factor: 3.064

2.  Peroxiredoxin 2 is involved in vasculogenic mimicry formation by targeting VEGFR2 activation in colorectal cancer.

Authors:  Shouru Zhang; Zhongxue Fu; Jinlai Wei; Jinbao Guo; Maoxi Liu; Kunli Du
Journal:  Med Oncol       Date:  2014-12-04       Impact factor: 3.064

3.  VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis.

Authors:  Qing Guo; Sheng-Bin Dai; Feng Shen; Di Yu; Shu-Tong Shen; Qu Zhang; Jun-Xing Huang; Zheng-Dong Wu
Journal:  Tumour Biol       Date:  2014-01-29

4.  Expression of molecular factors correlated with metastasis in small cell lung cancer and their significance.

Authors:  Xiao-Xia Li; Rui-Jian Li; Lu-Jun Zhao; Ning-Bo Liu; Ping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients.

Authors:  Nan Ma; Li-Wei Li; Jing-Liang Cheng
Journal:  Oncol Lett       Date:  2014-12-12       Impact factor: 2.967

6.  Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice.

Authors:  Tse-Hung Huang; Yi-Han Chiu; Yi-Lin Chan; Ya-Huang Chiu; Hang Wang; Kuo-Chin Huang; Tsung-Lin Li; Kuang-Hung Hsu; Chang-Jer Wu
Journal:  Mar Drugs       Date:  2015-04-03       Impact factor: 5.118

7.  Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Authors:  Ying Wang; Lu Huang; Shuqiang Wu; Yongshi Jia; Yunmei Yang; Limin Luo; Aihong Bi; Min Fang
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

8.  Effect of Avastin on the number and structure of tumor blood vessels of nude mice with A549 lung adenocarcinoma.

Authors:  Nali Zhang; Guojun Zhang; Youguang Zheng; Tongbing Wang; Honglei Wang
Journal:  Exp Ther Med       Date:  2014-09-24       Impact factor: 2.447

9.  Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.

Authors:  Erying Zhang; Xiaowei Feng; Fei Liu; Peihua Zhang; Jie Liang; Xudong Tang
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

10.  Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Rita Puskas; Andras Bikov; Peter Horvath; Zsofia Lazar; Laszlo Kunos; Reka Nagy; Gabriella Pinter; Gabriella Galffy
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.